Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Analysis to Evaluate the Effectiveness, Safety and Tolerability of Intravesical Valrubicin for the Treatment of Bladder Carcinoma in Situ in Clinical Practice

NCT01304173 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT01304173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01304173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Analysis to Evaluate the Effectiveness, Safety and Tolerability of Intravesical Valrubicin for the Treatment of Bladder Carcinoma in Situ in Clinical Practice
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Observational
Overall status
Completed
Start date
March 31, 2011
Completion date
October 31, 2011
Enrollment
113 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma in situ of bladder